INO vs IR · $88.0M cap vs P/E 49, $28.27B cap
Inovio Pharmaceuticals Inc (INO) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
Inovio Pharmaceuticals Inc (INO) is a biotechnology company listed on US.
Ingersoll Rand Inc (IR) common stock.
Latest reported INO revenue for 2026-06-30 was $0. Net income was -$6.0M. INO currently screens at market cap $88.0M.
IR does not have a complete income-statement cache yet.
INO currently screens at market cap $88.0M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the INO and IR stock pages for the full models.
Not investment advice.